期刊
CURRENT OPINION IN ORGAN TRANSPLANTATION
卷 27, 期 1, 页码 15-21出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOT.0000000000000941
关键词
acute rejection; biomarkers; kidney transplantation; noninvasive monitoring
资金
- Dr Dennis Ross Research Fund in Nephrology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Despite improvements in short-term outcomes post kidney transplantation, long-term outcomes are suboptimal. Novel molecular biomarkers are needed for reliable diagnosis and personalization of care for kidney transplant recipients. Recent advances have led to promising biomarker candidates, although challenges still exist in translating these biomarkers from bench to clinic.
Purpose of review Despite improvement in short-term outcomes after kidney transplantation, long-term outcomes remain suboptimal. Conventional biomarkers are limited in their ability to reliably identify early immunologic and nonimmunologic injury. Novel biomarkers are needed for noninvasive diagnosis of subclinical injury, prediction of response to treatment, and personalization of the care of kidney transplant recipients. Recent findings Recent biotechnological advances have led to the discovery of promising molecular biomarker candidates. However, translating potential biomarkers from bench to clinic is challenging, and many potential biomarkers are abandoned prior to clinical implementation. Despite these challenges, several promising urine, blood, and tissue novel molecular biomarkers have emerged and are approaching incorporation into clinical practice. This article highlights the challenges in adopting biomarker-driven posttransplant management and reviews several promising emerging novel biomarkers that are approaching clinical implementation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据